Efficacy of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta‐analysis

Abstract Background and Aim Molecular‐targeted agents such as lenvatinib and sorafenib have been approved to treat hepatocellular carcinoma (HCC). However, the choice between these two agents in the primary treatment for advanced HCC is still under debate with conflicting results. We sought to evalu...

Descrición completa

Detalles Bibliográficos

Principais autores:	Vikash Jaiswal, Maha Hameed, Sidra Naz, Poulami Roy, Novonil Deb, Janta Ukrani, Gautham Varun Krishna Mohan, Amira M Taha, Helen Huang, Vikash Kumar, Bhavyakumar Vachhani, Abdelrahman M Attia, Supti D Nath, Mostafa A Solimn, Dattatreya Mukherjee
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2023-12-01
Series:	JGH Open
Assuntos:	hepatocellular carcinoma lenvatinib mortality sorafenib
Acceso en liña:	https://doi.org/10.1002/jgh3.12999
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!